BIAL Biotech
About us
BIAL Biotech is a center of excellence for the development of genetically-defined Parkinson’s disease therapeutics located in the heart of the Boston biotech cluster. BIAL Biotech is a wholly owned subsidiary of BIAL.
View More
Science and Publications
BIAL Biotech is leveraging its expertise in lysosomal biology to develop novel small molecules to be used in the treatment of various neurodegenerative diseases. Our lead candidate, BIA 28-6156 / LTI-291, is being developed as a potential treatment for GBA-associated parkinsonism (GBA-AP).
View More
A targeted approach
There is a high, unmet need for medicines which address the fundamental causes of Parkinson’s disease and GBA-AP. Rather than merely providing symptomatic relief, therapies targeting the underlying biological causes could potentially slow disease progression for certain patients.
View More
PD and GBA1 Mutation
Parkinson’s disease (PD) is a chronic, degenerative neurological disorder that affects one in 100 people over the age of 60.
View More